Medivation (MDVN) to Acquire Rights to Cancer Drug from BioMarin Pharmaceuticals

Shares of Medivation Inc. (MDVN) were trading off -3.43 or -3.75 percent to $88.00 per share in Monday's premarket after the company announced early this morning it would be acquiring worldwide rights to talazoparib, a potential cancer treatment from BioMarin Pharmaceutical (BMRN). Medivation stock closed at $91.43, down -0.82 or -0.89 percent in Friday's regular ... READ MORE Read the rest of Medivation (MDVN) to Acquire Rights to Cancer Drug from BioMarin Pharmaceuticals at InvestorGuide.com .